Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anaemia

被引:20
作者
Benesch, M
Urban, C
Sykora, KW
Schwinger, W
Zintl, F
Lackner, H
Lang, P
Handgretinger, R
机构
[1] St Jude Childrens Res Hosp, Div Stem Cell Transplantat, Memphis, TN 38105 USA
[2] Karl Franzens Univ Graz, Dept Paediat Haematol Oncol, Graz, Austria
[3] Hannover Med Sch, Dept Paediat Haematol Oncol, D-3000 Hannover, Germany
[4] Univ Jena, Childrens Univ Hosp, D-6900 Jena, Germany
[5] Childrens Univ Hosp, Dept Paediat Haematol Oncol, Tubingen, Germany
关键词
severe aplastic anaemia; alternative donors; CD34(+) selection;
D O I
10.1111/j.1365-2141.2004.04857.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Without transplantation from a human leucocyte antigen-identical family donor, refractory severe aplastic anaemia (SAA) has an unfavourable prognosis. Conventional transplantation from a matched unrelated donor carries a high rate of mortality. We transplanted large numbers of highly purified CD34(+) cells from matched unrelated (n = 4), mismatched unrelated (n = 4) and mismatched related (n = 1) donors into nine children with refractory SAA. The grafts consisted of granulocyte colony-stimulating factor-mobilized peripheral positively selected CD34(+) cells. A median of 15.1 x 10(6)/kg CD34(+) stem cells and 11 x 10(3)/kg CD3(+) T-lymphocytes were infused. No additional pharmacological graft versus host disease (GVHD) prophylaxis was given. At a median follow-up of 47 (range 37-72) months, eight patients (89%) were in complete remission with >90% donor chimaerism and no evidence of GVHD. One patient died on day +238 as a consequence of GVHD. The use of highly purified mobilized CD34(+) stem cells warrants further clinical exploration in children with refractory SAA.
引用
收藏
页码:58 / 63
页数:6
相关论文
共 28 条
  • [1] Current results of bone marrow transplantation in patients with acquired severe aplastic anemia -: Report of the European group for blood and marrow transplantation
    Bacigalupo, A
    Oneto, R
    Bruno, B
    Socié, G
    Passweg, J
    Locasciulli, A
    Van Lint, MT
    Tichelli, A
    McCann, S
    Marsh, J
    Ljungman, P
    Hows, J
    Marin, P
    Schrezenmeier, H
    [J]. ACTA HAEMATOLOGICA, 2000, 103 (01) : 19 - 25
  • [2] Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients
    Bacigalupo, A
    Bruno, B
    Saracco, P
    Di Bona, E
    Locasciulli, A
    Locatelli, F
    Gabbas, A
    Dufour, C
    Arcese, W
    Testi, G
    Broccia, G
    Carotenuto, M
    Coser, P
    Barbui, T
    Leoni, P
    Ferster, A
    [J]. BLOOD, 2000, 95 (06) : 1931 - 1934
  • [3] BALDUZZI A, 1995, BLOOD, V86, P3247
  • [4] The modern management of severe aplastic anaemia
    Ball, SE
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (01) : 41 - 53
  • [5] CAMITTA BM, 1979, BLOOD, V53, P504
  • [6] CHAMPLIN RE, 1989, BLOOD, V73, P606
  • [7] Deeg H J, 1999, Biol Blood Marrow Transplant, V5, P243, DOI 10.1053/bbmt.1999.v5.pm10465104
  • [8] DEEG HJ, 1986, BLOOD, V68, P1363
  • [9] Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy
    Doney, K
    Leisenring, W
    Storb, R
    Appelbaum, FR
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 126 (02) : 107 - +
  • [10] Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA94 experience
    Fuhrer, M
    Burdach, S
    Ebell, W
    Gadner, H
    Haas, R
    Harbott, J
    Janka-Schaub, G
    Klingebiel, T
    Kremens, B
    Niemeyer, C
    Rampf, U
    Reiter, A
    Ritter, J
    Schulz, A
    Walther, U
    Zeidler, C
    Bender-Gotze, C
    [J]. KLINISCHE PADIATRIE, 1998, 210 (04): : 173 - 179